A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Recruiting

Phase 2

CabozantinibA Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Sponsor:

Nationwide Children's Hospital

Code:

NCT05135975

Conditions

Neuroblastoma

Sarcoma

Eligibility Criteria

Sex: All

Age: 18 - 40

Healthy Volunteers: Not accepted

Interventions

Cabozantinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-12. This information was provided to ClinicalTrials.gov by Nationwide Children's Hospital on 2025-08-12.